# US 2021/0330800 A1 · Albumin binding peptide conjugates and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330800 A1
- Document ID: US20210330800A1
- Status: Published application
- Kind: A1
- Application number: 17/371,367
- Filed: 2021-07-09
- Published: 2021-10-28
- Earliest claimed: 2017-08-09
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Kelly Dare MOYNIHAN; Rebecca Lynn HOLDEN; Darrell J. IRVINE; Bradley Lether PENTELUTE
- Web page: https://patentgrep.com/patent/US20210330800A1

## CPC

- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001192: {Glycoprotein 100 [Gp100]}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/76: Albumins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/6031: {Proteins}
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- A61K 2039/876: {Skin, melanoma}
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.

## Claims

### Claim 1

A method for increasing an immune response in a subject comprising administering to the subject an effective amount of a composition, wherein the composition comprises a conjugate comprising:
(a) an albumin binding peptide; and
(b) an immunomodulatory molecule,
wherein the albumin binding peptide is operatively coupled to the immunomodulatory molecule with or without a linker domain;
such that the composition increases the immune response in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immunomodulatory molecule further comprises a peptide antigen or an immunostimulatory oligonucleotide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method further comprises administering multiple doses of the conjugate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method further comprises administering the conjugate at various locations.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method further comprises administering the conjugate directly to a site in need of an immune response.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject has cancer or an infectious disease. The method of claim 1, wherein the albumin binding peptide is covalently linked to the immunomodulatory molecule, or the albumin binding peptide is operatively coupled to the immunomodulatory molecule via a linker domain.

### Claim 8 (depends on 7)

The method of claim 7, wherein the linker domain comprises a Gly-Ser linker or a polyethylene glycol (PEG) linker.

### Claim 9 (depends on 8)

The method of claim 8, wherein the Gly-Ser linker is a (Gly4Ser)n (SEQ ID NO: 44) linker, and wherein n is 1-6.

### Claim 10 (depends on 8)

The method of claim 8, wherein the PEG linker is a PEG2000 linker.

### Claim 11 (depends on 1)

The method of claim 1, wherein the immunomodulatory molecule comprises an immunomodulatory oligonucleotide.

### Claim 12 (depends on 11)

The method of claim 11, wherein the immunomodulatory oligonucleotide is CpG DNA.

### Claim 13 (depends on 1)

The method of claim 1, wherein the albumin binding peptide comprises the amino acid sequence DICLPRWGCLW (SEQ ID NO: 9).

### Claim 14 (depends on 1)

The method of claim 1, wherein the immunomodulatory molecule is a peptide antigen.

### Claim 15 (depends on 14)

The method of claim 14, wherein the peptide antigen is a cancer antigen or a melanoma antigen.

### Claim 16 (depends on 14)

The method of claim 14, wherein the peptide antigen is a tumor-associated antigen.

### Claim 17 (depends on 14)

The method of claim 14, wherein the peptide is generated from a viral or bacterial antigen or an allergen or an environmental antigen.

### Claim 18 (depends on 1)

The method of claim 1, wherein said composition further comprises a pharmaceutically acceptable carrier or excipient.

### Claim 19

A method for increasing an immune response in a subject comprising administering to the subject an effective amount of a vaccine comprising a composition for directing immunomodulatory molecules to the lymphatic system so as to increase the immune response in the subject and a pharmaceutically acceptable carrier or excipient, wherein the composition comprises a conjugate comprising:
(a) an albumin binding peptide; and
(b) an immunomodulatory molecule,
wherein the albumin binding peptide is operatively coupled to the immunomodulatory molecule with or without a linker domain.

### Claim 20 (depends on 19)

The method of claim 19, wherein the immunomodulatory molecule further comprises a peptide antigen or an immunostimulatory oligonucleotide.
